Toll-like receptor 9 agonists as cancer therapeutics

作者：Holtick Udo^*; Scheulen Max E; von Bergwelt Baildon Michael S; Weihrauch Martin R

来源：Expert Opinion on Investigational Drugs, 2011, 20(3): 361-372.

DOI：10.1517/13543784.2011.553187

• cancer
• immunotherapy
• TLR9 agonists
• vaccine

Areas covered: This review summarizes TLR9 signaling and the impact of TLR9 agonists on the immune response. The most recent experimental and clinical data are analyzed as well as the development of new TLR9 agonists in current clinical trials.
Expert opinion: Application of TLR9 agonists, in particular, combination strategies with chemo- or radiotherapy seem a promising and efficient immunotherapeutic approach in cancer patients even with refractory disease. Simultaneous application of TLR9 agonists aims at supporting the patient's immune response and overcoming specific immunosuppressant strategies developed by tumors. Combinatory approaches of the future might also seek for synergism of TLR9 agonists with other immunomodulatory strategies such as B-cell activation using the CD40--CD40L system.

• 出版日期2011-3